ISSN 1662-4009 (online)

ey0015.4-2 | Important for clinical practice | ESPEYB15

4.2 Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency-an analysis of KIGS data

W Bonfig , A Lindberg , M Carlsson , W Cutfield , D Dunger , C Camacho-Hübner , RW Holl

To read the full abstract: J Pediatr 2018; 198: 260-264The incidence of T1DM in children <15 years is increasing at an overall annual relative rate of 3.9% (95% CI 3.6-4.2) [11]. The prevalence of GHD is estimated at approximately 1:4000 to 1:10000 [12-14]. Management of the very rare patients who have both T1DM and GHD raises questions of efficacy and safety of ...

ey0015.8-7 | Important for Clinical Practice | ESPEYB15

8.7 Longitudinal assessment of illnesses, stress dosing and illness sequelae in patients with congenital adrenal hyperplasia

D El-Maouche , CJ Hargreaves , N Sinaii , A Mallappa , P Veeraraghavan , DP Merke

To read the full abstract: J Clin Endocrinol Metab. 2018; 103(6):2336-2345Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders characterized by impaired cortisol production in the adrenal cortex. Classic CAH represents the most common cause of primary adrenal insufficiency in childhood (10). Infant mortality in patients with CAH has decreased since the advent of...

ey0015.8-17 | New Paradigms | ESPEYB15

8.17 A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination

LR Strachan , TJ Stevenson , B Freshner , MD Keefe , D Miranda Bowles , JL Bonkowsky

To read the full abstract: Hum Mol Genet. 2017; 26(18): 3600-3614X-linked adrenoleukodystrophy (ALD) is caused by genetic mutations in the ABCD1 gene coding for a peroxisomal transmembrane protein responsible for the metabolism of very long chain fatty acids (VLCFA). It manifests with a broad phenotype mainly involving the peripheral and central nervous system and the adrenals. However, the exact pa...

ey0015.9-7 | Growth, growth hormone and puberty in chronic diseases: novel insights from clinical practice | ESPEYB15

9.7 Growth outcomes after GH therapy of patients given long-term corticosteroids for Juvenile Idiopathic Arthritis

H David , C Aupiais , B Louveau , P Quartier , E Jacqz-Aigrain , JC Carel , D Simon

To read the full abstract: J Clin Endocrinol Metab. 2017;102:4578-4587In chronic inflammatory diseases, inflammatory cytokines and exogenous glucocorticoid exposure affect growth through systemic effects on the GH–IGF-1 axis and local effects on the growth plates. Low plasma IGF-1 levels are related to systemic GH insufficiency or to hepatic GH resistance. Changes in IGF binding proteins ha...

ey0015.10-18 | Psychology and quality of life | ESPEYB15

10.18 Increasing risk of psychiatric morbidity after childhood onset T1DM: a population-based cohort study

D Dybdal , JS Tolstrup , SM Sildorf , KA Boisen , J Svensson , AM Skovgaard , GK Teilmann

To read the full abstract: Diabetologia. 2018;61:831-838T1DM in childhood and adolescence is a high burden for patients and family members. This is reflected by research that shows an increased incidence of psychiatric disorders in this patient group. Especially depression, eating disorders and anxiety disorders seem to be more prevalent. However data are mainly from small cohorts or regional...

ey0015.13-10 | Type 1 and Type 2 Diabetes in Resource-Limited Settings | ESPEYB15

13.10 Diabetes in sub-Saharan Africa: from clinical care to health policy

R Atun , JI Davies , EAM Gale , T Barnighausen , D Beran , AP Kengne

To read the full abstract: Lancet Diabetes Endocrinol 2017; 5(8):622-667The Lancet Diabetes and Endocrinology Commission provides a comprehensive, evidence-based review of diabetes in sub-Saharan Africa, one of the most important emerging diseases and markers of the global epidemic of non-communicable diseases. The authors provide a detailed analysis of the significant knowledge gaps in t...

ey0015.13-18 | Advances in the Diagnosis and Management of Congenital Hypothyroidism | ESPEYB15

13.18 Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism

L Mehran , D Khalili , S Yarahmadi , A Amouzegar , M Mojarrad , N Ajang , F Azizi

To read the full abstract: Int J Endocrinol Metab 2017; 15(3):e55451Systematic neonatal screening for congenital hypothyroidism (CH) was first proposed by Dr Jean Dussault, a Canadian (adult) endocrinologist, in 1974. It was rapidly implemented in most high-income countries in the late 1970’s and 1980’s. Ideally, a screening program should be highly sensitive (able to ...

ey0015.14-12 | The ‘nocebo’ effect: psychogenic but truly harmful | ESPEYB15

14.12 Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

A Gupta , D Thompson , A Whitehouse , T Collier , B Dahlof , N Poulter , R Collins , P Sever , Investigators ASCOT

To read the full abstract: Lancet 2017;389:2473-2481We are all familiar with the ‘placebo’ effect, when the psychological anticipation of a ‘benefit’ of treatment is so strong that it adds to or even outweighs the actual physical benefits. Many doctors have even admitted to prescribing placebo tablets, or “sugar pills” to their patients, for exam...

ey0020.3-2 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.2. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP

VM Breinholt , PH Mygind , ED Christoffersen , Y Zhang , S Ota , R Will Charlton , D Viuff

In Brief: This phase 1 study in healthy adults assessed the safety and feasibility of transcon-CNP, a novel prodrug that releases native C-type natriuretic peptide (CNP). The novel drug was well tolerated and CNP remained in systemic circulation for >7 days following a single dose.Commentary: Achondroplasia is caused by autosomal activating mutation in the fibroblast growth factor receptor 3 gene (FGFR3) resulting in constitutive receptor ac...

ey0020.5-6 | Clinical Guidance and Studies | ESPEYB20

5.6. Neuroimaging in 205 consecutive children diagnosed with central precocious puberty in Denmark

AB Hansen , CH Renault , D Wojdemann , P Gideon , A Juul , RB Jensen

Brief summary: This Danish single-center retrospective study evaluated the occurrence of pathological findings on neuroimaging among children diagnosed with central precocious puberty (CPP).CPP incidence has been increasing over the last four decades (1) and is more prevalent in females than in males. Most cases are idiopathic (2) but brain magnetic resonance imaging (MRI) is routinely performed in order to exclude rare pathological causes.<p class="...